Suchergebnisse - "Dexamethasone"

PubPharm (28.995)

71

Fluocinolone intravitreal implant (Iluvien) for macular edema secondary to immune recovery uveitis in patient with acute myeloid leukemia

enthalten in: Journal of ophthalmic inflammation and infection | 2024

von Cachero Rodríguez, J. | Artaraz, J. | Imaz, N. | +1

72

A TH17-intrinsic IL-1β-STAT5 axis drives steroid resistance in autoimmune neuroinflammation

enthalten in: Science immunology | 2024

von Miller-Little, W. | Chen, X. | Salazar, V. | +9

73

Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency

enthalten in: International journal of hematology | 2024

von Zhang, W. | Li, J. | Yamamoto, K. | +1

74

Fluocinolone intravitreal implant (Iluvien) for macular edema secondary to immune recovery uveitis in patient with acute myeloid leukemia

enthalten in: Journal of ophthalmic inflammation and infection | 2024

von Cachero Rodríguez, J. | Artaraz, J. | Imaz, N. | +1

75

Treatment of Acute Lymphoblastic Leukemia in Children : Treatment of Acute Lymphoblastic Leukemia in Children

enthalten in: ClinicalTrials.gov | 2024

76

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia : A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia

enthalten in: ClinicalTrials.gov | 2024

77

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) : A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

enthalten in: ClinicalTrials.gov | 2024

78

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue : A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

enthalten in: ClinicalTrials.gov | 2024

79

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma : Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

80

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma

enthalten in: European journal of haematology | 2024

von Dima, D. | Mansour, R. | Davis, J. | +9